Gene combinations of OBSCN, FAM83H, CLDN7 and ARFGAP3 significantly predicted the risk of re-occurrence after treatment, demonstrating that the genes identified through this screen can have high predictive value in patients and thus are potential prostate cancer biomarkers. Here, CLDN7 is linked to Familial prostate cancer.